Should I Buy SYK? SYK 2026 Analysis

Should You Buy Stryker Corp (SYK) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

354.300

1 Day change

-0.99%

52 Week Range

404.870

Analysis Updated At

2026/01/26

Stryker Corp (SYK) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows solid financial performance and has positive growth prospects in the medical device market, the current technical indicators and trading sentiment suggest a lack of immediate upward momentum. Additionally, insider and hedge fund selling, along with mixed analyst ratings, indicate caution. It is better to hold off for now and reassess after the upcoming earnings report on January 29, 2026.

Technical Analysis

The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 37.101, and moving averages are converging, showing no clear trend. The stock is trading near its support level of 352.559, with resistance at 360.478. Overall, the technical indicators suggest a lack of strong upward momentum.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

The U.S. medical device market is projected to grow at a CAGR of 6.8% from 2025 to 2032, benefiting Stryker.
The company anticipates 10% organic sales growth in its medical business for 2025, supported by strong market demand and new product launches.
Analysts like Bernstein and Raymond James highlight Stryker's strong fundamentals and attractive valuation.

Neutral/Negative Catalysts

Hedge funds and insiders are selling the stock significantly, indicating potential concerns.
The stock has declined by 6.1% over the past six months, underperforming peers.
Mixed analyst ratings and price target reductions from firms like Goldman Sachs and Evercore ISI.
Negative MACD and lack of clear technical momentum.

Financial Performance

In Q3 2025, Stryker's revenue increased by 10.25% YoY to $6.057 billion. Net income rose by 3% YoY to $859 million, and EPS grew by 2.78% YoY to $2.22. Gross margin improved slightly to 61.81%, up 0.32% YoY, indicating steady financial performance.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment is mixed. Some firms like Bernstein and Raymond James upgraded the stock, citing strong fundamentals and attractive valuation. Others like Goldman Sachs and Evercore ISI lowered price targets, citing macro uncertainties and sector rotation. Overall, analysts see potential upside in 2026 but remain cautious in the near term.

20 Analyst Rating

Wall Street analysts forecast SYK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SYK is 430.32 USD with a low forecast of 390 USD and a high forecast of 465 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

17 Buy

3 Hold

0 Sell

Strong Buy

Current: 357.830

Low

390

Averages

430.32

High

465

Current: 357.830

Low

390

Averages

430.32

High

465

TD Cowen

Buy

Hold

downgrade

$387

AI Analysis

2026-01-26

New

Reason

TD Cowen

Price Target

$387

AI Analysis

2026-01-26

New

downgrade

Buy

Hold

Reason

TD Cowen downgraded Stryker to Hold from Buy with a $387 price target as he took over coverage. While stating that "there's a lot we like about the story today and through decade-end," the firm thinks a "beat/raise precedent" is well understood and reflected in valuation. The firm would like to isolate underappreciated themes that can provide "unanticipated" upside to get more positive on the shares, the analyst tells investors.

Goldman Sachs

Neutral

downgrade

$418 -> $399

2026-01-09

Reason

Goldman Sachs

Price Target

$418 -> $399

2026-01-09

downgrade

Neutral

Reason

Goldman Sachs lowered the firm's price target on Stryker to $399 from $418 and keeps a Neutral rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SYK

Unlock Now

SYK Should I Buy

SYK Should I Buy

Should You Buy Stryker Corp (SYK) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch